

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	16	"6268391"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:25
L2	3	"7084147"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:27
L3	5	"6719339"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:27
L4	3	"7109333"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:50
L5	9	"6727256"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:04
L6	2	"7189734"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:50
L7	2	"7141576"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 11:11
L8	12	"6713485"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 11:11

EAST Search History

L9	7	"bRaf inhibitor"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:38
L10	64	"Raf inhibitor"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:38
L11	55	"Raf inhibitor" and "cancer"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:40
L12	10	"b-Raf inhibitor" and "cancer"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:33
L13	0	514/264.110	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34
L14	0	514/264.110.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34
L15	0	514/264.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34
L16	166	514/264.11.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34

EAST Search History

L17	22	514/264.11.ccls. and ("erbb2" or "raf")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:35
-----	----	---	--	----	-----	------------------

Search for

[Limits](#)
[Preview/Index](#)
[History](#)
[Clipboard](#)
[Details](#)

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

[About Entrez](#)
[Text Version](#)
[Entrez PubMed](#)
[Overview](#)
[Help | FAQ](#)
[Tutorials](#)
[New/Noteworthy](#) 
[E-Utilities](#)
[PubMed Services](#)
[Journals Database](#)
[MeSH Database](#)
[Single Citation Matcher](#)
[Batch Citation Matcher](#)
[Clinical Queries](#)
[Special Queries](#)
[LinkOut](#)
[My NCBI](#)
[Related Resources](#)
[Order Documents](#)
[NLM Mobile](#)
[NLM Catalog](#)
[NLM Gateway](#)
[TOXNET](#)
[Consumer Health](#)
[Clinical Alerts](#)
[ClinicalTrials.gov](#)
[PubMed Central](#)

Search

Most Recent Queries

Time Result

[#18](#) Search **b-raf and cancer**

14:42:48 [560](#)
[#17](#) Search **b-raf or braf and cancer**

14:42:25 [1009](#)
[#16](#) Search **b-raf or braf**

14:42:18 [1130](#)
[#15](#) Search **CFPAC-1**

12:32:35 [97](#)
[#13](#) Search **ERBB2 and leukemia**

12:15:08 [78](#)
[#12](#) Search **ERBB2 and cRaf-1**

12:14:39 [1](#)
[#11](#) Search **ERBB2 and cRaf-1 inhibitor**

12:14:35 [0](#)
[#9](#) Search **ERBB2 and Raf inhibitors**

12:14:07 [62](#)
[#8](#) Search **ERBB2 and Raf**

12:12:56 [111](#)
[#1](#) Search **GW572016**

12:10:04 [28](#)

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

10/510,542

4/16/07

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 18 CA/CAPLUS pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 4 DEC 18 CA/CAPLUS patent kind codes updated
NEWS 5 DEC 18 MARPAT to CA/CAPLUS accession number crossover limit increased
to 50,000
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7 DEC 27 CA/CAPLUS enhanced with more pre-1907 records
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 13 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 14 JAN 29 PHAR reloaded with new search and display fields
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19 FEB 26 MEDLINE reloaded with enhancements
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended
NEWS 26 MAR 20 MARPAT now updated daily
NEWS 27 MAR 22 LWPI reloaded
NEWS 28 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 29 MAR 30 INPADOCDB will replace INPADOC on STN
NEWS 30 APR 02 JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:10:44 ON 13 APR 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:10:57 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3

DICTIONARY FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10510542_specie.str



chain nodes :

11 18 19 20 27 33 34 35 36 37 38

ring nodes :

```

1  2  3  4  5  6  7  8  9  10  12  13  14  15  16  17  21  22  23  24  25  26  28
29 30 31 32
chain bonds :
3-28 7-11 11-12 15-19 16-18 19-20 20-21 25-27 30-33 33-34 34-35 35-36
36-37 37-38
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 21-22 21-26 22-23 23-24 24-25 25-26 28-29 28-32 29-30 30-31
31-32
exact/norm bonds :
7-11 11-12 15-19 28-29 28-32 29-30 30-31 31-32
exact bonds :
3-28 16-18 19-20 20-21 25-27 30-33 33-34 34-35 35-36 36-37 37-38
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 21-22 21-26 22-23 23-24 24-25 25-26

```

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS

```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 16:11:19 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 93 TO ITERATE

100.0% PROCESSED 93 ITERATIONS

12 ANSWERS

SEARCH TIME: 00.00.01

L2 12 SEA SSS FUL L1

=> s l1 exa full

FULL SEARCH INITIATED 16:11:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS

1 ANSWERS


SEARCH TIME: 00.00.01

L3 1 SEA EXA FUL L1

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 231277-92-2 REGISTRY
 ED Entered STN: 07 Aug 1999
 CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
 [[2-(methanesulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)
 OTHER NAMES:
 CN 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[2-
 methanesulfonylethyl]amino]methyl]furan-2-yl]quinazoline
 CN GW 572016
 CN Lapatinib
 MF C29 H26 Cl F N4 O4 S
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB,
 CHEMCATS, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, PROUSDDR,
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

135 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 136 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
232.30	232.51

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 16:11:56 ON 13 APR 2007

FILE 'CAPLUS' ENTERED AT 16:11:56 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:11:56 ON 13 APR 2007

COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 16:11:56 ON 13 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l3

SAMPLE SEARCH INITIATED 16:12:01 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 81
PROJECTED ANSWERS: 1 TO 40

L4 180 L3

=> s l3 not py>2003

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms. L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles. The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> s l4 not py>2003

L5 7 L4 NOT PY>2003

=> d l5 1-7 ibib, abs, hitstr

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:917646 CAPLUS Full-text
DOCUMENT NUMBER: 140:38051
TITLE: Epidermal Growth Factor Receptor Autocrine Signaling
in RIE-1 Cells Transformed by the Ras Oncogene
Enhances Radiation Resistance
AUTHOR(S): Grana, Theresa M.; Sartor, Carolyn I.; Cox, Adrienne
D.
CORPORATE SOURCE: Curriculum in Genetics and Molecular Biology,
Department of Radiation Oncology, University of North
Carolina, Chapel Hill, NC, USA
SOURCE: Cancer Research (2003), 63(22), 7807-7814
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Oncogenic forms of the small GTPase Ras increase the resistance of cells to
killing by ionizing radiation (IR). Although not all of the signaling
pathways for radioresistance are well defined, it is now clear that Ras-
dependent signaling pathways involved in radioresistance include those
mediated by phosphatidylinositol 3'-kinase (PI3-K) and Raf. Nevertheless,
PI3-K and Raf together are not sufficient to reconstitute all of the
resistance conferred by Ras, indicating that other effectors must also
contribute. We show here that Ras-driven autocrine signaling through the
epidermal growth factor receptor (EGFR) also contributes to radioresistance in
Ras-transformed cells. Conditioned media (CM) collected from RIE-1 rat
intestinal epithelial cells expressing oncogenic Ras increased the survival of
irradiated cells. Ras-CM contains elevated levels of the EGFR ligand


transforming growth factor α (TGF- α). Both Ras-CM and TGF- α stimulated EGFR phosphorylation, and exogenous TGF- α mimicked the effects of Ras-CM to increase radioresistance. Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells. Ras-CM and TGF- α also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016. Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer. The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.

IT 231277-92-2, GW572016

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ras utilizes autocrine signaling through EGF receptor to increase radioresistance in Ras-transformed cells and GW572016 acts as a radiosensitizer)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



REFERENCE COUNT: 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:8967 CAPLUS Full-text

DOCUMENT NUMBER: 139:62338

TITLE: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

AUTHOR(S): Laird, A. Douglas; Cherrington, Julie M.

CORPORATE SOURCE: SUGEN, Inc., South San Francisco, CA, 94080, USA

SOURCE: Expert Opinion on Investigational Drugs (2003), 12(1), 51-64

CODEN: EOIDER; ISSN: 1354-3784

PUBLISHER: Ashley Publications Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Numerous small mol. synthetic tyrosine kinase inhibitors are in clin. development for the treatment of human cancers. These fall into three

broad categories: inhibitors of the epidermal growth factor receptor tyrosine kinase family (e.g., Iressa and Tarceva), inhibitors of the split kinase domain receptor tyrosine kinase subgroup (e.g., PTK787/ZK 222584 and SU11248) and inhibitors of tyrosine kinases from multiple subgroups (e.g., Gleevec). In addition, agents targeting other tyrosine kinases implicated in cancer, such as Met, Tie-2 and Src, are in preclin. development. As experience is gained in the clinic, it has become clear that unleashing the full therapeutic potential of tyrosine kinase inhibitors will require patient preselection, better assays to guide dose selection, knowledge of mechanism-based side effects and ways to predict and overcome drug resistance.


IT 231277-92-2, GW-572016

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(small mol. tyrosine kinase inhibitors and clin. development of anticancer agents)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



REFERENCE COUNT: 127 THERE ARE 127 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:668812 CAPLUS Full-text

DOCUMENT NUMBER: 138:280796

TITLE: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

AUTHOR(S): Xia, Wenle; Mullin, Robert J.; Keith, Barry R.; Liu, Lei-Hua; Ma, Hong; Rusnak, David W.; Owens, Gary; Alligood, Krystal J.; Spector, Neil L.

CORPORATE SOURCE: GlaxoSmithKline, Department of Discovery Medicine, Research Triangle Park, North Carolina, NC, 27709-3398, USA

SOURCE: Oncogene (2002), 21(41), 6255-6263

CODEN: ONCNES; ISSN: 0950-9232

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English


not present

AB Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small mol., GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines. GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, resp. Complete inhibition of activated AKT in erbB2 overexpressing cells correlated with a 23-fold increase in apoptosis compared with vehicle controls. EGF, often elevated in cancer patients, did not reverse the inhibitory effects of GW572016. These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts. Erk1/2 and AKT represent potential biomarkers to assess the clin. activity of GW572016. Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.

IT 231277-92-2, GW 572016
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (GW572016 antitumor activity: dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
 DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L5 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:319330 USPATFULL Full-text

TITLE: Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy

INVENTOR(S): Singer, Thomas, Inzlingen, GERMANY, FEDERAL REPUBLIC OF
 Platz, Stefan, Ummendorf, GERMANY, FEDERAL REPUBLIC OF

Colbatzky, Florian, Stafflangen, GERMANY, FEDERAL
REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & CO. KG, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003225079	A1	20031204
APPLICATION INFO.:	US 2003-431699	A1	20030508 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10221018	20020511
	US 2002-389815P	20020618 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	896	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 231277-92-2

(EGFR-mediated signal transduction inhibitors for treatment of benign prostatic hyperplasia/prostatic hypertrophy)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



L5 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:251662 USPATFULL Full-text

TITLE: Heterocyclic compounds

INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES
Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176451	A1	20030918
APPLICATION INFO.:	US 2003-342810	A1	20030115 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-582746, filed on 30 Jun 2000, PENDING A 371 of International Ser. No. WO 1999-EP48, filed on 8 Jan 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3892	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	A process for the preparation of a compound of formula (I) ##STR1##	

comprising the steps:

(a) reacting a compound of formula (II) ##STR2##

wherein L and L' are suitable leaving groups, with a compound of formula (III)

UNH.sub.2 (III)

to prepare a compound of formula (IV) ##STR3##

and subsequently (b) substituting the group R^{sup.1} by replacement of the leaving group L'.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 231277-92-2P

(target compound; preparation of quinazolinamines and analogs as protein tyrosine kinase inhibitors)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



L5 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:214419 USPATFULL Full-text

TITLE: Use of tyrosine kinase inhibitors for the treatment of inflammatory processes

INVENTOR(S): Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF
Pueschner, Hubert, Biberach, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003149062	A1	20030807
APPLICATION INFO.:	US 2003-353616	A1	20030129 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10204462	20020205
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1686	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating inflammatory diseases of the airways or intestines which comprises administering substances selected from the group consisting of:

(a) quinazolines of general formula ##STR1##

wherein A, B, C, D, X, R.sup.a, R.sup.b, R.sup.c and n are as defined herein,

(b) the compounds

(1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylamino-cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine,

(2) 4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine, and

(3) 4-{[3-chloro-4-(3-fluoro-4-benzyloxy)-phenyl]amino}-6-(5-{[(2-methanesulfonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline or

(d) the antibodies Cetuximab C225, Trastuzumab, ABX-EGF and Mab ICR-62, and

(f) EGFR-antisense.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 231277-92-2

(tyrosine kinase inhibitors for treatment of pulmonary inflammatory conditions)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



=> FIL STNGUIDE
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
44.42	276.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

FILE 'STNGUIDE' ENTERED AT 16:13:21 ON 13 APR 2007
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Apr 6, 2007 (20070406/UP).

=> d his

(FILE 'HOME' ENTERED AT 16:10:44 ON 13 APR 2007)

FILE 'REGISTRY' ENTERED AT 16:10:57 ON 13 APR 2007

L1 STRUCTURE UPLOADED
 L2 12 S L1 FULL
 L3 1 S L1 EXA FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 16:11:56 ON 13 APR 2007

L4 180 S L3
 L5 7 S L4 NOT PY>2003

FILE 'STNGUIDE' ENTERED AT 16:13:21 ON 13 APR 2007

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.24	277.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

STN INTERNATIONAL LOGOFF AT 16:15:31 ON 13 APR 2007

***** STN Columbus *****

FILE 'HOME' ENTERED AT 16:16:10 ON 13 APR 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:16:38 ON 13 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3

DICTIONARY FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10510542_specie.str



chain nodes :

11 18 19 20 27 33 34 35 36 37 38

ring nodes :

1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 21 22 23 24 25 26 28
29 30 31 32

chain bonds :

3-28 7-11 11-12 15-19 16-18 19-20 20-21 25-27 30-33 33-34 34-35 35-36
36-37 37-38

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 21-22 21-26 22-23 23-24 24-25 25-26 28-29 28-32 29-30 30-31
31-32

exact/norm bonds :

7-11 11-12 15-19 28-29 28-32 29-30 30-31 31-32
exact bonds :
3-28 16-18 19-20 20-21 25-27 30-33 33-34 34-35 35-36 36-37 37-38
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 21-22 21-26 22-23 23-24 24-25 25-26

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS

L1 STRUCTURE UPLOADED

=> s l1 exa full

FULL SEARCH INITIATED 16:17:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L2 1 SEA EXA FUL L1

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 231277-92-2 REGISTRY

ED Entered STN: 07 Aug 1999

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)

OTHER NAMES:

CN 4-[[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[[2-
methanesulfonyl]ethyl]amino]methyl]furan-2-yl]quinazoline

CN GW 572016


CN Lapatinib

MF C29 H26 Cl F N4 O4 S

CI COM

SR CA

LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB,
CHEMCATS, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, PROUSDDR,
SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

135 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 136 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	60.20	60.41

FILE 'USPATFULL' ENTERED AT 16:17:17 ON 13 APR 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 12 Apr 2007 (20070412/PD)
 FILE LAST UPDATED: 12 Apr 2007 (20070412/ED)
 HIGHEST GRANTED PATENT NUMBER: US7203969
 HIGHEST APPLICATION PUBLICATION NUMBER: US2007083964
 CA INDEXING IS CURRENT THROUGH 12 Apr 2007 (20070412/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 12 Apr 2007 (20070412/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

=> s 12 .

L3 43 L2

=> s 13 and Raf

5746 RAF

L4 10 L3 AND RAF

=> d 14 1-10 ibib, abs

L4 ANSWER 1 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2007:11185 USPATFULL Full-text

TITLE: Methods of treating cancer

INVENTOR(S): Potter, David A., Indianapolis, IN, UNITED STATES

PATENT ASSIGNEE(S): Indianan University Advanced Research (U.S. corporation)

Technology Institute, a Indiana corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007009593	A1	20070111
APPLICATION INFO.:	US 2006-451875	A1	20060613 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-629045, filed on 28 Jul 2003, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-399573P	20020726 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	1506	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a patient will respond to a particular method of treatment are also described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2006:253838 USPATFULL <u>Full-text</u>
TITLE:	Combinations for the treatment of cancer
INVENTOR(S):	Chang, David, Calabasas, CA, UNITED STATES
PATENT ASSIGNEE(S):	Amgen Inc, Thousand Oaks, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006216288	A1	20060928
APPLICATION INFO.:	US 2006-386271	A1	20060321 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-664381P	20050322 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AMGEN INC., MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1584	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2006:208454 USPATFULL Full-text
TITLE: Inhibiting HER2 shedding with matrix metalloprotease antagonists
INVENTOR(S): Carey, Kendall D., South San Francisco, CA, UNITED STATES
Schwall, Ralph, Pacifica, CA, UNITED STATES
Sliwkowski, Mark, San Carlos, CA, UNITED STATES
Schwall, Gail Colbern, Pacifica, CA, UNITED STATES
legal representative
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006177448	A1	20060810
APPLICATION INFO.:	US 2006-351811	A1	20060209 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-651348P	20050209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	3198	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes using antagonists of matrix metalloproteases (MMPs), especially of MMP-15, for inhibiting HER2 shedding.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2006:131781 USPATFULL Full-text
TITLE: Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
INVENTOR(S): Zeligs, Michael A., Boulder, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006111423	A1	20060525
APPLICATION INFO.:	US 2005-260543	A1	20051026 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-622333P	20041026 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2738	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes compositions and methods for the treatment and prevention of conditions associated with Human Cytomegalovirus (HCMV) infection. HCMV-associated conditions include infections (active and latent), benign cell-proliferative conditions, pre-cancerous cell-proliferative conditions, and cancerous conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3'-diindolylmethane (DIM), or a DIM-related indole, in combination with an inhibitor of a membrane bound Growth Factor Receptor (GFR), to treat conditions associated with exposure to HCMV. In certain embodiments, the compositions of the invention can be used in combination with radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2005:261902 USPATFULL Full-text
TITLE: Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
INVENTOR(S): Masferrer, Jaime L., Ballwin, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005227929	A1	20051013
APPLICATION INFO.:	US 2004-989192	A1	20041115 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-519701P	20031113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Harness, Dickey & Pierce, P.L.C., Suite 400, 7700 Bonhomme, St. Louis, MO, 63105, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	12553	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising a Cox-2 inhibitor and an antineoplastic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2005:255665 USPATFULL Full-text
TITLE: Combinations of signal transduction inhibitors
INVENTOR(S): Eck, Stephen Louis, Ann Arbor, MI, UNITED STATES
Fry, David William, Ypsilanti, MI, UNITED STATES
Leopold, Judith Ann, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): PFIZER INC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005222163	A1	20051006
APPLICATION INFO.:	US 2005-95442	A1	20050330 (11)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2004-557623P 20040330 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10777 SCIENCE CENTER
DRIVE, SAN DIEGO, CA, 92121, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 3071

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl- pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2005:203315 USPATFULL Full-text
TITLE: Cancer treatment method comprising administering an
erb-family inhibitor and a raf and/or ras
inhibitor
INVENTOR(S): Spector, Neil Lee, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

APPLICATION

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005176740	A1	20050811
APPLICATION INFO.:	US 2003-510542	A1	20030408 (10)
	WO 2003-US10747		20030408

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-370807P	20020408 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	3918	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an

erb family inhibitor and a Raf and/or ras inhibitor to a mammal suffering from a cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2005:157855 USPATFULL Full-text
TITLE: Anti-IGFR antibody therapeutic combinations
INVENTOR(S): Wang, Yan, Scotch Plains, NJ, UNITED STATES
Pachter, Jonathan A., Chatham, NJ, UNITED STATES
Bishop, Walter Robert, Pompton Plains, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005136063	A1	20050623
APPLICATION INFO.:	US 2004-993395	A1	20041119 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-524732P	20031121 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2883	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides combinations including a binding composition, such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent. Methods for using the combinations to treat medical conditions, such as cancer, are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2004:216030 USPATFULL Full-text
TITLE: Methods of treating cancer
INVENTOR(S): Potter, David A., Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004167139	A1	20040826
APPLICATION INFO.:	US 2003-629045	A1	20030728 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-399573P	20020726 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	

LINE COUNT: 1653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a patient will respond to a particular method of treatment are also described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2004:70718 USPATFULL Full-text

TITLE: Cancer treatment method

INVENTOR(S): Lackey, Karen Elizabeth, Durham, NC, UNITED STATES
Spector, Neil, Durham, NC, UNITED STATES
Wood III, Edgar Raymond, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053946	A1	20040318
	US 7141576	B2	20061128
APPLICATION INFO.:	US 2003-466290	A1	20030715 (10)
	WO -US201130		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	1780		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:16:10 ON 13 APR 2007)

FILE 'REGISTRY' ENTERED AT 16:16:38 ON 13 APR 2007

L1 STRUCTURE UPLOADED

L2 1 S L1 EXA FULL

FILE 'USPATFULL' ENTERED AT 16:17:17 ON 13 APR 2007

L3 43 S L2

L4 10 S L3 AND RAF

=> d 13 1-43 ibib, abs

L3 ANSWER 1 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2007:68538 USPATFULL Full-text

TITLE: Biomarkers in cancer
INVENTOR(S): Bacus, Sarah S., Hinsdale, IL, UNITED STATES
Spector, Neil Lee, Durham, NC, UNITED STATES
PATENT ASSIGNEE(S): SMITHKLINE BEECHAM CORPORATION, Philadelphia, PA,
UNITED STATES, 19101 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007059785	A1	20070315
APPLICATION INFO.:	US 2004-568251	A1	20040810 (10)
	WO 2004-US26434		20040810
			20060214 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-495325P	20030815 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1555	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Biomarkers may be used in the treatment of cancer, and as an aid in clinical decision making regarding which anti-cancer therapy to use in a particular patient. Described herein are methods of assessing whether a subject with a solid tumor is suitable for treatment with a dual EGFR/erbB2 tyrosine kinase inhibitor, by assessing the relative localization of pERK or pAKT in tumor cells, and/or assessing pre-treatment tumor cell levels of ErbB2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2007:43082 USPATFULL Full-text
TITLE: Novel combinations of medicaments for the treatment of
respiratory diseases containing long-acting
beta-agonists and at least one additional active
ingredient
INVENTOR(S): KONETZKI, Ingo, Warthausen, GERMANY, FEDERAL REPUBLIC
OF
BOUYSSOU, Thierry, Birkenhard, GERMANY, FEDERAL
REPUBLIC OF
PESTEL, Sabine, Attenweiler, GERMANY, FEDERAL REPUBLIC
OF
SCHNAPP, Andreas, Biberach, GERMANY, FEDERAL REPUBLIC
OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007037781	A1	20070215
APPLICATION INFO.:	US 2006-424558	A1	20060616 (11)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: DE 2005-10200503073320050701
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,
900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 4559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 ##STR1## wherein the groups X, R.sup.a, R.sup.b, R.sup.1, R.sup.1', R.sup.2, R.sup.2', R.sup.2'', V and n may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2007:18058 USPATFULL Full-text
TITLE: HETEROCYCLIC COMPOUNDS
INVENTOR(S): Carter, Malcom Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES
Smith, Kathryn Jane, Hertfordshire, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007015775	A1	20070118
APPLICATION INFO.:	US 2006-532926	A1	20060919 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2005-50033, filed on 3 Feb 2005, GRANTED, Pat. No. US 7109333 Continuation of Ser. No. US 2003-342810, filed on 15 Jan 2003, PENDING		

COMP. CLAIM

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112
	WO 1999-EP48	19990108
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3572	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the preparation of a compound of formula (I) ##STR1## comprising the steps: (a) reacting a compound of formula (II) ##STR2## wherein L and L' are suitable leaving groups, with a compound of formula (III) UNH.sub.2 (III) to prepare a compound of formula (IV) ##STR3##

and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2007:17079 USPATFULL Full-text
TITLE: EGFR inhibitors promote axon regeneration
INVENTOR(S): He, Zhigang, Boston, MA, UNITED STATES
Koprivica, Vuk, Boston, MA, UNITED STATES
PATENT ASSIGNEE(S): Children's Medical Center Corporation (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007014792	A1	20070118
APPLICATION INFO.:	US 2005-180070	A1	20050712 (11)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	RICHARD ARON OSMAN, SCIENCE AND TECHNOLOGY LAW GROUP, 242 AVE VISTA DEL OCEANO, SAN CLEMENTE, CA, 92672, US		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	761		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2007:11185 USPATFULL Full-text
TITLE: Methods of treating cancer
INVENTOR(S): Potter, David A., Indianapolis, IN, UNITED STATES
PATENT ASSIGNEE(S): Indianan University Advanced Research (U.S.
corporation)
Technology Institute, a Indiana corporation (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007009593	A1	20070111
APPLICATION INFO.:	US 2006-451875	A1	20060613 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-629045, filed on 28 Jul 2003, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-399573P	20020726 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	1506	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a patient will respond to a particular method of treatment are also described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 43 USPATFULL on STN

NOT PUBLISHED

ACCESSION NUMBER: 2006:307823 USPATFULL Full-text
TITLE: Combinations and modes of administration of therapeutic agents and combination therapy
INVENTOR(S): Desai, Neil P., Santa Monica, CA, UNITED STATES
Soon-Shiong, Patrick, Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006263434	A1	20061123
APPLICATION INFO.:	US 2006-359286	A1	20060221 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-654245P	20050218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018, US	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	4403	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 43 USPATFULL on STN

NOT PUBLISHED

ACCESSION NUMBER: 2006:253838 USPATFULL Full-text
TITLE: Combinations for the treatment of cancer
INVENTOR(S): Chang, David, Calabasas, CA, UNITED STATES
PATENT ASSIGNEE(S): Amgen Inc, Thousand Oaks, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006216288	A1	20060928
APPLICATION INFO.:	US 2006-386271	A1	20060321 (11)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 2005-664381P 20050322 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMGEN INC., MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE,
THOUSAND OAKS, CA, 91320-1799, US
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is in the field of pharmaceutical agents and specifically
relates to compounds, compositions, uses and methods for treating cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:240521 USPATFULL Full-text
TITLE: Treatment of cancers expressing p95 erbb2
INVENTOR(S): Spector, Neil Lee, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006204966	A1	20060914
APPLICATION INFO.:	US 2004-567012	A1	20040802 (10)
	WO 2004-532488		20040802
			20060201 PCT 371 date

TREATMENT
w/ GW572016
(inhibitor compd.)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-491752P	20030801 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	1213	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The truncated ErbB2 receptor (p95.sup.ErbB2) is shown to differ from the
full-length ErbB2 receptor in its association with other ErbB receptors. The
truncated receptor preferentially associated with ErbB3, whereas full length
ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with
p95.sup.ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an
ErbB3 ligand) stimulates p95.sup.ErbB2 phosphorylation in breast cancer cell
lines. Described herein are methods of identifying patients suitable for
treatment with a p95.sup.ErbB2 inhibitor, and methods of treating such
patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:222351 USPATFULL Full-text
TITLE: Anilinoquinazolinones as protein tyrosine kinase
inhibitors
INVENTOR(S): Cockerill, George Stuart, Maulden, UNITED KINGDOM

Lackey, Karen Elizabeth, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006189637	A1	20060824
	US 7189734	B2	20070313
APPLICATION INFO.:	US 2006-400284	A1	20060407 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2005-61578, filed on 18 Feb 2005, PENDING Division of Ser. No. US 2002-30527, filed on 9 Jan 2002, GRANTED, Pat. No. US 6933299		

Compos
COMPOSITIONS

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-16213	19990709
	GB 1999-16218	19990709
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4471	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 43 USPATFULL on STN

ACCESSION NUMBER:	2006:209365 USPATFULL <u>Full-text</u>
TITLE:	Use of EGFR tyrosinkinase inhibitors for treatment of chronic rhinosinusitis
INVENTOR(S):	Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF Disse, Bernd, Mainz, GERMANY, FEDERAL REPUBLIC OF Pohl, Gerald, Biberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S):	Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006178364	A1	20060810
APPLICATION INFO.:	US 2006-275903	A1	20060202 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-10200500550520050204	
	DE 2005-10200503621620050802	
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	838	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of selected EGFR kinase inhibitors, particularly selected quinazolines, quinolines and pyrimido-pyrimidines, for the treatment of nasal polyposis and chronic rhinosinusitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:208454 USPATFULL Full-text
TITLE: Inhibiting HER2 shedding with matrix metalloprotease antagonists
INVENTOR(S): Carey, Kendall D., South San Francisco, CA, UNITED STATES
Schwall, Ralph, Pacifica, CA, UNITED STATES
Sliwowski, Mark, San Carlos, CA, UNITED STATES
Schwall, Gail Colbern, Pacifica, CA, UNITED STATES
legal representative
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006177448	A1	20060810
APPLICATION INFO.:	US 2006-351811	A1	20060209 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-651348P	20050209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	3198	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes using antagonists of matrix metalloproteases (MMPs), especially of MMP-15, for inhibiting HER2 shedding.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:208384 USPATFULL Full-text
TITLE: Method for monitoring early treatment response
INVENTOR(S): Norfray, Joseph F., Glenview, IL, UNITED STATES
PATENT ASSIGNEE(S): RECEPTOMON, LLC, Glenview, IL, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006177378	A1	20060810
APPLICATION INFO.:	US 2005-193037	A1	20050729 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2005-53059, filed on 8 Feb 2005, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE		

4900, 180 NORTH STETSON AVENUE, CHICAGO, IL,
60601-6780, US

NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 976

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor, for example, a VEGF inhibitor, whereby a decrease in the amount of Choline after treatment is indicative of a positive response. The decrease in the amount of Choline represents the decrease in the internal cell membrane as a result of down regulation of the organelles and their secretory granules and their transport vesicles. Disclosed also is a method for determining effectiveness of an angiogenesis inhibitor in the treatment of cancer. Also disclosed are methods of monitoring early treatment response in diseases where an angiogenesis effector, i.e., an inhibitor or promoter of angiogenesis, is employed. Also disclosed is a method for monitoring protein translation related to angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:208383 USPATFULL Full-text
TITLE: Method for monitoring early treatment response
INVENTOR(S): Norfray, Joseph F., Glenview, IL, UNITED STATES
PATENT ASSIGNEE(S): Receptomon, LLC., Glenview, IL, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006177377	A1	20060810
APPLICATION INFO.:	US 2005-53059	A1	20050208 (11)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780, US		

NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 907

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor, for example, a VEGF inhibitor, whereby a decrease in the amount of Choline after treatment is indicative of a positive response. The decrease in the amount of Choline represents the decrease in the internal cell membrane as a result of down regulation of the organelles and their secretory granules and their transport vesicles. Disclosed also is a method for determining effectiveness of an angiogenesis inhibitor in the treatment of cancer. Also disclosed are methods of monitoring early treatment response in diseases where an

angiogenesis effector, i.e., an inhibitor or promoter of angiogenesis, is employed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:151492 USPATFULL Full-text
TITLE: Targeted therapy marker panels
INVENTOR(S): Bacus, Sarah S., Hinsdale, IL, UNITED STATES
Hill, Jason, Chicago, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006127928	A1	20060615
APPLICATION INFO.:	US 2005-223700	A1	20050909 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-635198P	20041210 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BRINKS HOFER GILSON & LIONE, P.O. BOX 10395, CHICAGO, IL, 60610, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	25 Drawing Page(s)	
LINE COUNT:	2055	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:131781 USPATFULL Full-text
TITLE: Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
INVENTOR(S): Zeligs, Michael A., Boulder, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006111423	A1	20060525
APPLICATION INFO.:	US 2005-260543	A1	20051026 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-622333P	20041026 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	54	

EXEMPLARY CLAIM: 1
LINE COUNT: 2738

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes compositions and methods for the treatment and prevention of conditions associated with Human Cytomegalovirus (HCMV) infection. HCMV-associated conditions include infections (active and latent), benign cell-proliferative conditions, pre-cancerous cell-proliferative conditions, and cancerous conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3'-diindolylmethane (DIM), or a DIM-related indole, in combination with an inhibitor of a membrane bound Growth Factor Receptor (GFR), to treat conditions associated with exposure to HCMV. In certain embodiments, the compositions of the invention can be used in combination with radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:111124 USPATFULL Full-text
TITLE: Predictive markers in cancer therapy
INVENTOR(S): Bacus, Sarah S., Tuscon, AZ, UNITED STATES
Herrle, Myra R., Durham, NC, UNITED STATES
Kirk, L. Edward, Durham, NC, UNITED STATES
Spector, Neil L., Durham, NC, UNITED STATES
Stocum, Michael T., Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006094068	A1	20060504	
APPLICATION INFO.:	US 2003529922	A1	20030424	(10)
	WO 2003US12739		20030424	
			20050330	PCT 371 date

NOT TREATMENT
METHODS

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-389795P	20020619 (60)
	US 2002-432811P	20021211 (60)
	US 2002-432943P	20021211 (60)
	US 2003-451978P	20030305 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI
B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE
PARK, NC, 27709-3398, US

NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1595

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Molecular markers useful in medicine response tests are provided, as an aid in determining whether an individual subject s tumor is responding to treatment with EGF and/or erbB2 inhibitors. Markers include phosphorylated ERK protein

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:99440 USPATFULL Full-text
TITLE: Combined therapy against tumors comprising substituted
acryloyl distamycin derivatives and protein kinase
(serine/threonine kinase) inhibitors
INVENTOR(S): Geroni, Maria Cristina, Via Correggio 48, Milan, ITALY
I-20149
Fowst, Camilla, Milan, ITALY
Cozzi, Paolo, Milan, ITALY

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006084612	A1	20060420
APPLICATION INFO.:	US 2002-500606	A1	20021218 (10)
	WO 2002-EP13092		20021218
			20050505 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2002-75052	20020102
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Peter I Bernstein, Scully Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, NY, 11530, US	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	458	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides the combined use of acryloyl distamycin derivatives, in particular α -bromo- and α -chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and a protein kinase (serine/threonine and tyrosine kinases) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:41241 USPATFULL Full-text
TITLE: Pharmaceutical compositions for treatment of
respiratory and gastrointestinal disorders
INVENTOR(S): Jung, Birgit, Biberach, GERMANY, FEDERAL REPUBLIC OF
Himmelsbach, Frank, Mittelbiberach, GERMANY, FEDERAL
REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006035893	A1	20060216
APPLICATION INFO.:	US 2005-189643	A1	20050726 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-18808	20040807
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,	

900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 8735

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK.sub.1 antagonists and endothelin-antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:318073 USPATFULL Full-text
TITLE: Antibody-drug conjugates and methods
INVENTOR(S): Ebens, Allen J. JR., San Carlos, CA, UNITED STATES
Jacobson, Frederic S., Berkeley, CA, UNITED STATES
Polakis, Paul, Burlingame, CA, UNITED STATES
Schwall, Ralph H., Pacifica, CA, UNITED STATES
Sliwowski, Mark X., San Carlos, CA, UNITED STATES
Spencer, Susan D., Tiburon, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005276812	A1	20051215
APPLICATION INFO.:	US 2005-141344	A1	20050531 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-616098P	20041005 (60)
	US 2004-576517P	20040601 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	4618	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D).sub.p I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:313136 USPATFULL Full-text

TITLE: Method for treating abnormal cell growth
INVENTOR(S): Denis, Louis J., Pawcatuck, CT, UNITED STATES
Compton, Linda D., Richland, MI, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005272755	A1	20051208
APPLICATION INFO.:	US 2005-145097	A1	20050603 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-577268P	20040604 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Pfizer Inc, 150 East 42nd Street, 5th Floor - Stop 49, New York, NY, 10017-5612, US	
NUMBER OF CLAIMS:	95	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2926	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b) a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug of said pyrimidine derivative; and (c) an anti-tumor agent selected from the group consisting of antiproliferative agents, kinase inhibitors, angiogenesis inhibitors, growth factor inhibitors, cox-I inhibitors, cox-II inhibitors, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, anti-androgens and combinations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 21 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:275215 USPATFULL Full-text

TITLE: Novel medicament combinations for the treatment of respiratory diseases

INVENTOR(S): Konetzki, Ingo, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Bouyssou, Thierry, Mietingen, GERMANY, FEDERAL REPUBLIC OF
Lustenberger, Philipp, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC OF
Schnapp, Andreas, Biberach, GERMANY, FEDERAL REPUBLIC OF
Hoenke, Christoph, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Pestel, Sabine, Attenweiler, GERMANY, FEDERAL REPUBLIC OF
Rudolf, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239778	A1	20051027
APPLICATION INFO.:	US 2005-109094	A1	20050419 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-1020	20040422
	DE	20041103
	EP 2005-2496	20050207
	US 2004-578542P	20040610 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	4182	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 ##STR1## wherein the groups R.sup.1, R.sup.2 and R.sup.3 may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 22 OF 43 USPATFULL on STN
 ACCESSION NUMBER: 2005:261902 USPATFULL Full-text
 TITLE: Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
 INVENTOR(S): Masferrer, Jaime L., Ballwin, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005227929	A1	20051013
APPLICATION INFO.:	US 2004-989192	A1	20041115 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-519701P	20031113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Harness, Dickey & Pierce, P.L.C., Suite 400, 7700 Bonhomme, St. Louis, MO, 63105, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	12553	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising a Cox-2 inhibitor and an antineoplastic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 23 OF 43 USPATFULL on STN

NOT PLEDA ANT

ACCESSION NUMBER: 2005:255665 USPATFULL Full-text
TITLE: Combinations of signal transduction inhibitors
INVENTOR(S): Eck, Stephen Louis, Ann Arbor, MI, UNITED STATES
Fry, David William, Ypsilanti, MI, UNITED STATES
Leopold, Judith Ann, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): PFIZER INC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005222163	A1	20051006
APPLICATION INFO.:	US 2005-95442	A1	20050330 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-557623P	20040330 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AGOURON PHARMACEUTICALS, INC., 10777 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121, US	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3071	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 24 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:234149 USPATFULL Full-text
TITLE: Medicament combinations based on scopine- or tropene
acid esters with EGFR-kinase inhibitors
INVENTOR(S): Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC
OF
Pohl, Gerald, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 2005203088 A1 20050915
APPLICATION INFO.: US 2005-28268 A1 20050103 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-10200400	20040109
	US 2004-557082P	20040326 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1783	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel drug compositions based on compounds of general formula 1 ##STR1## wherein X.sup.- and the groups A, B, R, R.sup.1, R.sup.2, R.sup.3, R.sup.3', R.sup.4 and R.sup.4' may have the meanings given in the claims and in the specification and EGFR kinase inhibitors, processes for preparing them and their use in the treatment of respiratory complaints.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 25 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:203315 USPATFULL Full-text

TITLE: Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor

INVENTOR(S): Spector, Neil Lee, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

APPLICATION

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005176740	A1	20050811
APPLICATION INFO.:	US 2003-510542	A1	20030408 (10)
	WO 2003-US10747		20030408

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-370807P	20020408 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	3918	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a Raf and/or ras inhibitor to a mammal suffering from a cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 26 OF 43 USPATFULL on STN

NOT PLEAD AMT

ACCESSION NUMBER: 2005:190097 USPATFULL Full-text
TITLE: Pharmaceutical compositions containing anticholinergics
and EGFR kinase inhibitors
INVENTOR(S): Meade, Christopher J. M., Maselheim, GERMANY, FEDERAL
REPUBLIC OF
Pairret, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC
OF
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005165013	A1	20050728
APPLICATION INFO.:	US 2005-87153	A1	20050323 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-614382, filed on 7 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10230751	20020709
	US 2002-407746P	20020903 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1455	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based on
new anticholinergics and EGFR kinase inhibitors, processes for preparing
them and their use in the treatment of respiratory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

NOT PLEAD AMT

L3 ANSWER 27 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:171858 USPATFULL Full-text
TITLE: Preventives and/or remedies for subjects with the
expression or activation of her2 and/or egfr
INVENTOR(S): Suzuki, Tsuyoshi, Tokyo, JAPAN
Kitano, Yasunori, Tokyo, JAPAN
Yano, Shinji, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005148607	A1	20050707
APPLICATION INFO.:	US 2003-516360	A1	20030603 (10)
	WO 2003-JP6988		20030603

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2002-162130	20020603
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W.,
 SUITE 800, WASHINGTON, DC, 20006-1021, US
 NUMBER OF CLAIMS: 26
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Page(s)
 LINE COUNT: 1033

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A Her2 and/or EGFR inhibitor to be administered to a subject determined to show overexpression or activation of Her2 and/or EGFR as a result of a diagnosis of the subject for the expression or activity of Her2 and/or EGFR based on a test for detecting the expression or activity of Her2 and/or EGFR, and a pharmaceutical composition containing the inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 28 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:171813 USPATFULL Full-text
 TITLE: Pharmaceutical compositions based on anticholinergics and additional active ingredients
 INVENTOR(S): Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
 Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC OF
 Meade, Christopher John Montague, Maselheim, GERMANY, FEDERAL REPUBLIC OF
 Reichl, Richard, Gau-Algesheim, GERMANY, FEDERAL REPUBLIC OF
 Schmelzer, Christel, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
 Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005148562	A1	20050707
APPLICATION INFO.:	US 2004-6940	A1	20041208 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-776757, filed on 11 Feb 2004, PENDING Continuation of Ser. No. US 2001-86145, filed on 19 Oct 2001, ABANDONED		
	Continuation-in-part of Ser. No. US 2004-775901, filed on 10 Feb 2004, PENDING Continuation of Ser. No. US 2001-27662, filed on 20 Dec 2001, ABANDONED		
	Continuation-in-part of Ser. No. US 2003-613783, filed on 3 Jul 2003, PENDING Continuation of Ser. No. US 2002-93240, filed on 7 Mar 2002, ABANDONED		
	Continuation-in-part of Ser. No. US 2004-763894, filed on 23 Jan 2004, PENDING Continuation of Ser. No. US 2003-419358, filed on 21 Apr 2003, GRANTED, Pat. No. US 6696042 Continuation of Ser. No. US 2002-92116, filed on 6 Mar 2002, GRANTED, Pat. No. US 6620438		
	Continuation-in-part of Ser. No. US 2003-413065, filed on 14 Apr 2003, ABANDONED Continuation of Ser. No. US 2002-100659, filed on 18 Mar 2002, GRANTED, Pat. No. US 6608054 Continuation-in-part of Ser. No. US 2004-824391, filed on 14 Apr 2004, PENDING Continuation of Ser. No. US 2001-7182, filed on 19 Oct 2001, ABANDONED Continuation-in-part of Ser. No. US 2003-360064, filed on 7 Feb 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10054042	20001031
	DE 2000-10062712	20001215
	DE 2000-10063957	20001220
	DE 2001-110772	20010307
	DE 2001-111058	20010308
	DE 2001-113366	20010320
	DE 2001-138272	20010810
	DE 2002-10206505	20020216
	US 2000-257220P	20001221 (60)
	US 2000-253613P	20001128 (60)
	US 2000-257221P	20001221 (60)
	US 2001-281857P	20010405 (60)
	US 2001-281653P	20010405 (60)
	US 2001-281874P	20010405 (60)
	US 2001-314599P	20010824 (60)
	US 2000-253613P	20001128 (60)
	US 2002-369213P	20020401 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,
900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT,
06877-0368, US

NUMBER OF CLAIMS: 238
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 4621

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising an anticholinergic and at least one additional active ingredient selected from among corticosteroids, dopamine agonistes, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 29 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:165976 USPATFULL Full-text
TITLE: Anilinoquinazaolines as protein tyrosine kianse inhibitors

INVENTOR(S): Cockerill, George Stuart, Maulden, UNITED KINGDOM
Lackey, Karen Elizabeth, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005-143401	A1	20050630
	US 7084147	B2	20060801
APPLICATION INFO.:	US 2005-61578	A1	20050218 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-303527, filed on 25 Nov 2002, GRANTED, Pat. No. US 6719339		

Compd & Compositions

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-16213	19990709
	GB 1999-16218	19990709
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY,
GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH
TRIANGLE PARK, NC, 27709-3398, US

NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 4418

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heteroaromatic compounds are described, methods for their preparation,
pharmaceutical compositions containing them, methods of use, and their use
in medicines. In particular, the invention relates to quinazoline and
pyridopyrimidine derivatives which exhibit protein tyrosine kinase
inhibition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 30 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:157855 USPATFULL Full-text *NOT PAPER PAT*
TITLE: Anti-IGFR antibody therapeutic combinations
INVENTOR(S): Wang, Yan, Scotch Plains, NJ, UNITED STATES
Pachter, Jonathan A., Chatham, NJ, UNITED STATES
Bishop, Walter Robert, Pompton Plains, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005136063	A1	20050623
APPLICATION INFO.:	US 2004-993395	A1	20041119 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-524732P	20031121 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2883	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides combinations including a binding composition,
such as an anti-IGFR1 antibody, in association with a chemotherapeutic
agent. Methods for using the combinations to treat medical conditions, such
as cancer, are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 31 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:152082 USPATFULL Full-text
TITLE: Heterocyclic compounds
INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES
Smith, Kathryn Jane, Hertfordshire, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005130996	A1	20050616
	US 7109333	B2	20060919
APPLICATION INFO.:	US 2005-50033	A1	20050203 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-342810, filed on 15 Jan 2003, PENDING Continuation of Ser. No. US 2000-582746, filed on 30 Jun 2000, GRANTED, Pat. No. US 6727256 A 371 of International Ser. No. WO 1999-EP48, filed on 8 Jan 1999		

METHOD OF INHIBITING EGFR: c-erbB2

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3538	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the preparation of a compound of formula (I) ##STR1## comprising the steps: (a) reacting a compound of formula (II) ##STR2## wherein L and L' are suitable leaving groups, with a compound of formula (III) UNH.sub.2 (III) to prepare a compound of formula (IV) ##STR3## and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 32 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2005:138638 USPATFULL Full-text

TITLE: Dosing schedule for a novel anticancer agent

INVENTOR(S): Bhattacharya, Samit Kumar, Groton, CT, UNITED STATES
Connell, Richard Damian, East Lyme, CT, UNITED STATES
Jani, Jitesh, East Lyme, CT, UNITED STATES
Moyer, James Dale, East Lyme, CT, UNITED STATES
Noe, Dennis A., Madison, CT, UNITED STATES
Steyn, Stefanus Johannes, Oakdale, CT, UNITED STATES

PATENT ASSIGNEE(S): Pfizer Inc (U.S. corporation)

NOT PAPER PAT

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005119288	A1	20050602
APPLICATION INFO.:	US 2004-919831	A1	20040817 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-495919P	20030818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	1877	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to methods for the a method for treating overexpression of the erbB2 in a mammal in need of treatment by administering to the mammal a therapeutically effective amount of a first inhibitor of an erbB2 receptor and then, after an interval of less than 24 hours, administering to the mammal from one to six therapeutically effective amounts of the same or different inhibitor of the erbB2 receptor. The invention is also directed to a slow daily infusion of the erbB2 inhibitor. The overexpression of the erbB2 receptor can result in abnormal cell growth and lead to cancer. By the methods of the invention, the efficacy and safety of the inhibitors is increased. The invention is also directed to kits for facilitating the dose administration method of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 33 OF 43 USPATFULL on STN

WIT PAFUR MAT

ACCESSION NUMBER: 2004:292296 USPATFULL Full-text
TITLE: ErbB heterodimers as biomarkers
INVENTOR(S): Chan-Hui, Po-Ying, Oakland, CA, UNITED STATES
Dua, Rajiv, Manteca, CA, UNITED STATES
Mukherjee, Ali, Belmont, CA, UNITED STATES
Pidaparathi, Sailaja, Cupertino, CA, UNITED STATES
Salimi-Moosavi, Hossein, Sunnyvale, CA, UNITED STATES
Shi, Yining, San Jose, CA, UNITED STATES
Singh, Sharat, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004229380	A1	20041118
APPLICATION INFO.:	US 2004-813412	A1	20040330 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-154042, filed on 21 May 2002, PENDING Continuation-in-part of Ser. No. US 2003-623057, filed on 17 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-494482P	20030811 (60)
	US 2003-508034P	20031001 (60)
	US 2003-512941P	20031020 (60)
	US 2003-523258P	20031118 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ACLARA BIOSCIENCES, INC., 1288 PEAR AVENUE, MOUNTAIN VIEW, CA, 94043
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 36 Drawing Page(s)
LINE COUNT: 2951

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to a new class of biomarker in patient samples comprising heterodimers of Her cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more heterodimers of ErbB, or Her, cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more heterodimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a

pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 34 OF 43 USPATFULL on STN

NOT REFIN ANT

ACCESSION NUMBER: 2004:292210 USPATFULL Full-text
TITLE: ErbB surface receptor complexes as biomarkers
INVENTOR(S): Chan-Hui, Po-Ying, Oakland, CA, UNITED STATES
Dua, Rajiv, Manteca, CA, UNITED STATES
Mukherjee, Ali, Belmont, CA, UNITED STATES
Pidaparthi, Sailaja, Cupertino, CA, UNITED STATES
Salimi-Moosavi, Hossein, Sunnyvale, CA, UNITED STATES
Shi, Yining, San Jose, CA, UNITED STATES
Singh, Sharat, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004229294	A1	20041118
APPLICATION INFO.:	US 2004-813417	A1	20040330 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-154042, filed on 21 May 2002, PENDING Continuation-in-part of Ser. No. US 2003-623057, filed on 17 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459888P	20030401 (60)
	US 2003-494482P	20030811 (60)
	US 2003-508034P	20031001 (60)
	US 2003-512941P	20031020 (60)
	US 2003-523258P	20031118 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ACLARA BIOSCIENCES, INC., 1288 PEAR AVENUE, MOUNTAIN VIEW, CA, 94043

NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 36 Drawing Page(s)
LINE COUNT: 3181

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of

receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 35 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2004:216030 USPATFULL Full-text

TITLE: Methods of treating cancer

INVENTOR(S): Potter, David A., Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004167139	A1	20040826
APPLICATION INFO.:	US 2003-629045	A1	20030728 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-399573P	20020726 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	1653	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a patient will respond to a particular method of treatment are also described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 36 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2004:165980 USPATFULL Full-text

TITLE: Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist

INVENTOR(S): Masferrer, Jaime, Ballwin, MO, UNITED STATES

PATENT ASSIGNEE(S): Pharmacia Corporation, St. Louis, MO, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004127470	A1	20040701
APPLICATION INFO.:	US 2003-651916	A1	20030829 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-470951, filed on 22 Dec 1999, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113786P	19981223 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: Charles E. Dunlap, Nelson Mullins Riley & Scarborough,
LLP, P.O. Box 11070, Columbia, SC, 29211-1070

NUMBER OF CLAIMS: 34

EXEMPLARY CLAIM: 1

LINE COUNT: 8937

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one Cox-2 inhibitor in combination with an EGF receptor antagonist. Compositions, pharmaceutical compositions and kits are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 37 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2004:103738 USPATFULL Full-text

TITLE: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, United States
Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6727256	B1	20040427
	WO 9935146		19990715
APPLICATION INFO.:	US 2000-582746		20000630 (9)
	WO 1999-EP48		19990108
			20000630 PCT 371 date

METHOD OF TREATING
CANCER ~/
INSTANT COMPD.
(NOT COMBINATION)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Rotman, Alan L.	
ASSISTANT EXAMINER:	Truong, Tamthom N.	
LEGAL REPRESENTATIVE:	Lemanowicz, John L.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3829	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted heteroaromatic compounds of formula (I), wherein X is N or CH; Y is CR^{sup.1} and V is N; or Y is N and V is CR^{sup.1}; or Y is CR^{sup.1} and V is CR^{sup.2}; or Y is CR^{sup.2} and V is CR^{sup.1}; R^{sup.1} represents a group CH₃SO₂CH₂CH₂NHCH₂Ar, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C₁-4alkyl or C₁-4alkoxy groups; R^{sup.2} is selected from the group comprising hydrogen, halo, hydroxy, C₁-4alkyl, C₁-4alkoxy, C₁-4alkylamino and di[C₁-4alkyl]amino; U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-

benzotriazolyl group, substituted by an R.sup.3 group and optionally substituted by at least one independently selected R.sup.4 group; R.sup.3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl, or R.sup.3 represents trihalomethylbenzyl or trihalomethylbenzyloxy; or R.sup.3 represents a group of formula (a) wherein each R.sup.5 is independently selected from halogen, C.sub.1-4alkyl, C.sub.1-4alkoxy; and n is 0 to 3; each R.sup.4 is independently hydroxy, halogen, C.sub.1-4alkyl, C.sub.2-4alkenyl, C.sub.2-4alkynyl, C.sub.1-4alkoxy, amino, C.sub.1-4alkylamino, di[C.sub.1-4alkyl]amino, C.sub.1-4alkylthio, C.sub.1-4alkylsulphonyl, C.sub.1-4alkylsulphonyl, C.sub.1-4alkylcarbonyl, carboxy, carbamoyl, C.sub.1-4alkoxycarbonyl, C.sub.1-4alkanoylamino, N-(C.sub.1-4alkyl)carbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 38 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2004:70718 USPATFULL Full-text

TITLE: Cancer treatment method

INVENTOR(S): Lackey, Karen Elizabeth, Durham, NC, UNITED STATES
Spector, Neil, Durham, NC, UNITED STATES
Wood lll, Edgar Raymond, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053946	A1	20040318
	US 7141576	B2	20061128
APPLICATION INFO.:	US 2003-466290	A1	20030715 (10)
	WO -US201130		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	1780		

INSTANT COPY +
PALLIATIVE FOR
BREAST CANCER

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 39 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2004:64368 USPATFULL Full-text

TITLE: Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors

INVENTOR(S): Meade, Christopher J. M., Bingen, GERMANY, FEDERAL
REPUBLIC OF
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC
OF

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF, 55216 (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048887	A1	20040311
APPLICATION INFO.:	US 2003-614382	A1	20030707 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10230751	20020709
	US 2002-407746P	20020903 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1486	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based on
new anticholinergics and EGFR kinase inhibitors, processes for preparing
them and their use in the treatment of respiratory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 40 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2003:319330 USPATFULL Full-text

TITLE: Use of inhibitors of the EGFR-mediated signal
transduction for the treatment of benign prostatic
hyperplasia (BPH)/prostatic hypertrophy

INVENTOR(S): Singer, Thomas, Inzlingen, GERMANY, FEDERAL REPUBLIC OF
Platz, Stefan, Ummendorf, GERMANY, FEDERAL REPUBLIC OF
Colbatzky, Florian, Stafflangen, GERMANY, FEDERAL
REPUBLIC OF

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & CO. KG, Ingelheim,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003225079	A1	20031204
APPLICATION INFO.:	US 2003-431699	A1	20030508 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10221018	20020511
	US 2002-389815P	20020618 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	896	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of specific EGF-receptor
antagonists for preparing a pharmaceutical composition for the prevention

and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 41 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2003:251662 USPATFULL Full-text

TITLE: Heterocyclic compounds

INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES
Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176451	A1	20030918
APPLICATION INFO.:	US 2003-342810	A1	20030115 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-582746, filed on 30 Jun 2000, PENDING A 371 of International Ser. No. WO 1999-EP48, filed on 8 Jan 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3892	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the preparation of a compound of formula (I) ##STR1##

comprising the steps:

(a) reacting a compound of formula (II) ##STR2##

wherein L and L' are suitable leaving groups, with a compound of formula (III)

UNH.sub.2 (III)

to prepare a compound of formula (IV) ##STR3##

and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 42 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2003:214419 USPATFULL Full-text

TITLE: Use of tyrosine kinase inhibitors for the treatment of inflammatory processes

INVENTOR(S): Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF
Pueschner, Hubert, Biberach, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003149062	A1	20030807
APPLICATION INFO.:	US 2003-353616	A1	20030129 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10204462	20020205
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1686	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating inflammatory diseases of the airways or intestines which comprises administering substances selected from the group consisting of:

(a) quinazolines of general formula ##STR1##

wherein A, B, C, D, X, R.sup.a, R.sup.b, R.sup.c and n are as defined herein,

(b) the compounds

(1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylamino-cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine,

(2) 4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine, and

(3) 4-{[3-chloro-4-(3-fluoro-4-benzyloxy)-phenyl]amino}-6-(5-{[(2-methanesulphonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline or

(d) the antibodies Cetuximab C225, Trastuzumab, ABX-EGF and Mab ICR-62, and

(f) EGFR-antisense.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 43 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2002:266326 USPATFULL Full-text

TITLE: Heterocyclic compounds

INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES
Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147205	A1	20021010
	US 6713485	B2	20040330
APPLICATION INFO.:	US 2002-71358	A1	20020208 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-582746, filed on 30 Jun 2000, PENDING		

TREATMENT OF
CANCER W/ CLAIMED
COMPOUND

O.D.P.

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112
	WO 1999-EP48	19990108
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, DURHAM, NC, 27709-3398	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3860	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase activity, in particular erbB-2 and/or EGFR activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:16:10 ON 13 APR 2007)

FILE 'REGISTRY' ENTERED AT 16:16:38 ON 13 APR 2007

L1 STRUCTURE UPLOADED

L2 1 S L1 EXA FULL

FILE 'USPATFULL' ENTERED AT 16:17:17 ON 13 APR 2007

L3 43 S L2

L4 10 S L3 AND RAF

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

113.90

174.31

STN INTERNATIONAL LOGOFF AT 16:19:32 ON 13 APR 2007